High efficacy of brigatinib for brain metastases in ALK fusion gene‐positive non‐small cell lung cancer: A case series

Abstract Anaplastic lymphoma kinase (ALK) fusion gene‐positive lung cancer often shows brain metastasis at initial diagnosis or during the course of treatment. However, molecular‐targeted drugs are known to pass through the blood–brain barrier and present positive effects for central nervous system...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kei Morikawa, Yu Numata, Yusuke Shinozaki, Shotaro Kaneko, Aya Matsushima, Makoto Nishida, Hirotaka Kida, Hiroshi Handa, Hiroki Nishine, Masamichi Mineshita
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2024-02-01
coleção:	Thoracic Cancer
Assuntos:	ALK fusion gene‐positive lung cancer brain metastasis brigatinib non‐small cell lung cancer (NSCLC) tyrosine kinase inhibitors (TKIs)
Acesso em linha:	https://doi.org/10.1111/1759-7714.15207
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!